Head-To-Head Review: AEON Biopharma (NASDAQ:AEON) vs. Silverback Therapeutics (NASDAQ:SBTX)

AEON Biopharma (NASDAQ:AEON) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares AEON Biopharma and Silverback Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	$5.04	0.22
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-4.14

Silverback Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

AEON Biopharma has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for AEON Biopharma and Silverback Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	1	1	1	3.00
Silverback Therapeutics	0	0	0	0	0.00

Profitability

This table compares AEON Biopharma and Silverback Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Insider and Institutional Ownership

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 0.9% of AEON Biopharma shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

AEON Biopharma beats Silverback Therapeutics on 8 of the 11 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.